Clinical Trial Update: Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Hu3S193 in women with ovarian epithelial, primary peritoneal, or fallopian tube cancer has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Hu3S193

Snippet

Sponsor: Recepta Biopharma | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-11-26